

In this issue

Case Report

[Open Access](#) [Case Report](#) PTZAID:OJCPS-1-101

[Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions](#)

Published On: October 01, 2018 | Pages: 001 - 005

Author(s): Caixia Deng, Hu Luo and Xiangdong Zhou*

So far, in the advanced non-small cell lung cancer (NSCLC) with clear epidermal growth factor receptor (EGFR) gene status, the treatment remmendations has reached an agreement: for patients with EGFR mutation-positive, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the first choice, which can maximize the benefit from the treatment; while f ...

[Abstract View](#) | [Full Article View](#) | DOI: [10.17352/ojcps.000001](https://doi.org/10.17352/ojcps.000001)